3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Glioblastoma
52
Brain Neoplasms
28
Glioma
22
Gliosarcoma
19
Melanoma
18
Astrocytoma
17
Central Nervous System Neoplasms
11
Oligodendroglioma
10
Neoplasms
9
Neoplasm Metastasis
8
Recurrence
6
Carcinoma, Non-Small-Cell Lung
5
Neuroblastoma
4
Lymphoma
4
Ependymoma
4
Diffuse Intrinsic Pontine Glioma
3
Breast Neoplasms
3
Sarcoma, Ewing
2
Neurologic Manifestations
2
Neuroectodermal Tumors, Primitive
2
Neoplasms, Second Primary
2
Meningeal Carcinomatosis
2
Medulloblastoma
2
Bone Neoplasms
2
Urinary Bladder Neoplasms
1
Thrombocytopenia
1
Tetanus
1
Spinal Cord Neoplasms
1
Solid Tumors
1
Small Cell Lung Cancer Recurrent
1
Interventions
Carboplatin
4
Sunitinib
3
Rituximab
3
Pemetrexed
3
ponatinib
2
pembrolizumab
2
osimertinib
2
Vincristine
2
Prednisone
2
Gemcitabine
2
Etoposide
2
Doxorubicin
2
Cyclophosphamide
2
ricolinostat
1
pralsetinib
1
pomalidomide
1
nilotinib
1
linifanib
1
ibritumomab tiuxetan
1
emvododstat
1
atezolizumab
1
Temozolomide
1
Taxes
1
Sorafenib
1
Papanicolaou Test
1
Paclitaxel
1
Melphalan
1
Irinotecan
1
Interleukin-2
1
Imatinib Mesylate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Neoplasms by Histologic Type
×
Temozolomide
×
Clear all
NCT03495921
2023-04-26
VITA
Gradalis, Inc.
Phase 3
Terminated
32 enrolled
13 charts